Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations
Neurodegenerative diseases are progressive and uncontrolled gradual loss of motor neurons function or death of neuron cells in the central nervous system (CNS) and the mechanisms underlying their progressive nature remain elusive. There is urgent need to investigate therapeutic strategies and novel...
Uloženo v:
| Vydáno v: | Current stem cell research & therapy Ročník 15; číslo 2; s. 102 |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United Arab Emirates
01.01.2020
|
| Témata: | |
| ISSN: | 2212-3946, 2212-3946 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Neurodegenerative diseases are progressive and uncontrolled gradual loss of motor neurons function or death of neuron cells in the central nervous system (CNS) and the mechanisms underlying their progressive nature remain elusive. There is urgent need to investigate therapeutic strategies and novel treatments for neural regeneration in disorders like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Currently, the development and identification of pluripotent stem cells enabling the acquisition of a large number of neural cells in order to improve cell recovery after neurodegenerative disorders. Pluripotent stem cells which consist of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are characterized by their ability to indefinitely self-renew and the capacity to differentiate into different types of cells. The first human ESC lines were established from donated human embryos; while, because of a limited supply of donor embryos, human ESCs derivation remains ethically and politically controversial. Hence, hiPSCs-based therapies have been shown as an effective replacement for human ESCs without embryo destruction. Compared to the invasive methods for derivation of human ESCs, human iPSCs has opened possible to reprogram patient-specific cells by defined factors and with minimally invasive procedures. Human pluripotent stem cells are a good source for cell-based research, cell replacement therapies and disease modeling. To date, hundreds of human ESC and human iPSC lines have been generated with the aim of treating various neurodegenerative diseases. In this review, we have highlighted the recent potentials, advances, and limitations of human pluripotent stem cells for the treatment of neurodegenerative disorders. |
|---|---|
| AbstractList | Neurodegenerative diseases are progressive and uncontrolled gradual loss of motor neurons function or death of neuron cells in the central nervous system (CNS) and the mechanisms underlying their progressive nature remain elusive. There is urgent need to investigate therapeutic strategies and novel treatments for neural regeneration in disorders like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Currently, the development and identification of pluripotent stem cells enabling the acquisition of a large number of neural cells in order to improve cell recovery after neurodegenerative disorders. Pluripotent stem cells which consist of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are characterized by their ability to indefinitely self-renew and the capacity to differentiate into different types of cells. The first human ESC lines were established from donated human embryos; while, because of a limited supply of donor embryos, human ESCs derivation remains ethically and politically controversial. Hence, hiPSCs-based therapies have been shown as an effective replacement for human ESCs without embryo destruction. Compared to the invasive methods for derivation of human ESCs, human iPSCs has opened possible to reprogram patient-specific cells by defined factors and with minimally invasive procedures. Human pluripotent stem cells are a good source for cell-based research, cell replacement therapies and disease modeling. To date, hundreds of human ESC and human iPSC lines have been generated with the aim of treating various neurodegenerative diseases. In this review, we have highlighted the recent potentials, advances, and limitations of human pluripotent stem cells for the treatment of neurodegenerative disorders. Neurodegenerative diseases are progressive and uncontrolled gradual loss of motor neurons function or death of neuron cells in the central nervous system (CNS) and the mechanisms underlying their progressive nature remain elusive. There is urgent need to investigate therapeutic strategies and novel treatments for neural regeneration in disorders like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Currently, the development and identification of pluripotent stem cells enabling the acquisition of a large number of neural cells in order to improve cell recovery after neurodegenerative disorders. Pluripotent stem cells which consist of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are characterized by their ability to indefinitely self-renew and the capacity to differentiate into different types of cells. The first human ESC lines were established from donated human embryos; while, because of a limited supply of donor embryos, human ESCs derivation remains ethically and politically controversial. Hence, hiPSCs-based therapies have been shown as an effective replacement for human ESCs without embryo destruction. Compared to the invasive methods for derivation of human ESCs, human iPSCs has opened possible to reprogram patient-specific cells by defined factors and with minimally invasive procedures. Human pluripotent stem cells are a good source for cell-based research, cell replacement therapies and disease modeling. To date, hundreds of human ESC and human iPSC lines have been generated with the aim of treating various neurodegenerative diseases. In this review, we have highlighted the recent potentials, advances, and limitations of human pluripotent stem cells for the treatment of neurodegenerative disorders.Neurodegenerative diseases are progressive and uncontrolled gradual loss of motor neurons function or death of neuron cells in the central nervous system (CNS) and the mechanisms underlying their progressive nature remain elusive. There is urgent need to investigate therapeutic strategies and novel treatments for neural regeneration in disorders like Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Currently, the development and identification of pluripotent stem cells enabling the acquisition of a large number of neural cells in order to improve cell recovery after neurodegenerative disorders. Pluripotent stem cells which consist of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are characterized by their ability to indefinitely self-renew and the capacity to differentiate into different types of cells. The first human ESC lines were established from donated human embryos; while, because of a limited supply of donor embryos, human ESCs derivation remains ethically and politically controversial. Hence, hiPSCs-based therapies have been shown as an effective replacement for human ESCs without embryo destruction. Compared to the invasive methods for derivation of human ESCs, human iPSCs has opened possible to reprogram patient-specific cells by defined factors and with minimally invasive procedures. Human pluripotent stem cells are a good source for cell-based research, cell replacement therapies and disease modeling. To date, hundreds of human ESC and human iPSC lines have been generated with the aim of treating various neurodegenerative diseases. In this review, we have highlighted the recent potentials, advances, and limitations of human pluripotent stem cells for the treatment of neurodegenerative disorders. |
| Author | Nikkar, Negin Khoshnam, Seyed Esmaeil Kolagar, Tannaz Akbari Farzaneh, Maryam |
| Author_xml | – sequence: 1 givenname: Tannaz Akbari surname: Kolagar fullname: Kolagar, Tannaz Akbari organization: Faculty of Biological Sciences, Tehran North Branch, Islamic Azad University, Tehran, Iran – sequence: 2 givenname: Maryam surname: Farzaneh fullname: Farzaneh, Maryam organization: Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran – sequence: 3 givenname: Negin surname: Nikkar fullname: Nikkar, Negin organization: Department of Biology, Faculty of Sciences, Alzahra University, Tehran, Iran – sequence: 4 givenname: Seyed Esmaeil surname: Khoshnam fullname: Khoshnam, Seyed Esmaeil organization: Physiology Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31441732$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkE1LxDAURYOM6Dj6FyTuXFhNXpM2cTeMHyMMOqCCu5o2rxJo07FJB_z3Fh3B1buLcy-8c0QmvvNIyBlnl8BzccVlLpRSb1xkWcY1U5ByAZrzPTIF4JCkWmSTf_mAHI6E4HkKU_K-HFrj6boZerfpIvpInyO2dIFNE6jz9BGHvrP4gR57E90W6Y0LaAKGa7r-KTjThAs6t1vjKwzUeEtXrnVxpDsfjsl-PQJ4srsz8np3-7JYJqun-4fFfJWUUrCYGCtqxLKspZRlzqWqJNNpBZkFLrCWGbe2ylWpK42gAZErUHUtFePMsJrBjJz_7m767nPAEIvWhWr8wnjshlBAmmZ6tDO6mZHTHTqULdpi07vW9F_FnxX4Bp4LZeA |
| CitedBy_id | crossref_primary_10_3389_fcimb_2025_1641366 crossref_primary_10_1093_brain_awad392 crossref_primary_10_1080_01616412_2021_1893564 crossref_primary_10_3390_cells14191486 crossref_primary_10_3892_ijmm_2023_5331 crossref_primary_10_3390_ijms252212378 crossref_primary_10_1186_s12964_021_00753_8 crossref_primary_10_3389_fcell_2024_1346996 crossref_primary_10_1242_dmm_049543 crossref_primary_10_1515_revneuro_2023_0006 crossref_primary_10_4103_1673_5374_332131 crossref_primary_10_1016_j_neurobiolaging_2020_07_030 crossref_primary_10_1021_jacs_5c07724 crossref_primary_10_3390_polym15122674 crossref_primary_10_4252_wjsc_v17_i2_98693 crossref_primary_10_1016_j_jphs_2025_05_002 crossref_primary_10_3390_biomedicines11010120 crossref_primary_10_3389_fpsyt_2022_925012 crossref_primary_10_1177_09636897241282792 crossref_primary_10_3390_nano11092337 crossref_primary_10_1002_ibra_12095 crossref_primary_10_1097_BS9_0000000000000215 crossref_primary_10_7759_cureus_89629 crossref_primary_10_1007_s12975_020_00853_6 crossref_primary_10_1002_adhm_202100581 crossref_primary_10_3390_bioengineering10121378 crossref_primary_10_3390_ijms241612699 crossref_primary_10_1186_s13287_020_01998_9 crossref_primary_10_3390_pharmaceutics15030770 crossref_primary_10_4103_NRR_NRR_D_23_01897 crossref_primary_10_1016_j_addr_2025_115525 crossref_primary_10_1186_s12964_021_00725_y crossref_primary_10_1016_j_omtm_2025_101415 crossref_primary_10_1159_000528886 crossref_primary_10_3389_fcell_2022_967147 crossref_primary_10_3389_fncel_2021_811852 crossref_primary_10_3390_ijms23031184 crossref_primary_10_1007_s13204_022_02698_x |
| ContentType | Journal Article |
| Copyright | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| Copyright_xml | – notice: Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| DBID | NPM 7X8 |
| DOI | 10.2174/1574888X14666190823142911 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| EISSN | 2212-3946 |
| ExternalDocumentID | 31441732 |
| Genre | Journal Article |
| GroupedDBID | NPM 7X8 |
| ID | FETCH-LOGICAL-b540t-ad4feebbf555b7158c5093c26d214ef561ddc78b9c9e292ee1828ff58010a0f02 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 53 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000522151600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2212-3946 |
| IngestDate | Fri Jul 11 14:15:30 EDT 2025 Thu Jan 02 22:58:32 EST 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Parkinson's disease Neurodegenerative diseases Induced pluripotent stem cells embryonic stem cells multiple sclerosis Alzheimer's disease amyotrophic lateral sclerosis |
| Language | English |
| License | Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-b540t-ad4feebbf555b7158c5093c26d214ef561ddc78b9c9e292ee1828ff58010a0f02 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| PMID | 31441732 |
| PQID | 2336990814 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2336990814 pubmed_primary_31441732 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-01-01 |
| PublicationDateYYYYMMDD | 2020-01-01 |
| PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United Arab Emirates |
| PublicationPlace_xml | – name: United Arab Emirates |
| PublicationTitle | Current stem cell research & therapy |
| PublicationTitleAlternate | Curr Stem Cell Res Ther |
| PublicationYear | 2020 |
| Score | 2.422639 |
| SecondaryResourceType | review_article |
| Snippet | Neurodegenerative diseases are progressive and uncontrolled gradual loss of motor neurons function or death of neuron cells in the central nervous system (CNS)... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 102 |
| Title | Human Pluripotent Stem Cells in Neurodegenerative Diseases: Potentials, Advances and Limitations |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31441732 https://www.proquest.com/docview/2336990814 |
| Volume | 15 |
| WOSCitedRecordID | wos000522151600003&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjxga_6YgseDe3u5rVepFSLBy0BH-QWN_uQQk2qSf39zm5SPAmCl9wWwjD55vtmNvMhdMG4CZh1DcglB4GieejxPNQepUKFkS9C6TwjX-6jySROU560DbeqvVa5xEQH1KqUtkfep4yFgJwx8a_nH551jbLT1dZCYxV1GFAZ-2FGqTOho3YXH_fDDdSzt52Bd_dJEEG2xilgAxQlZ_VNAI0J-Z1cuiIz3v7v6-2grZZe4mGTD7toRRd76NV16nEyWwBClECSa_xY63c80rNZhacFdhs6lH5zK6gt_uGbZm5TXeHEHbBZeomHzYWBCotCYfdrVNPv20fP49un0Z3XOit4OTC02hPKN1rnuQmCII9IEEvgDUzSUFHiawOcSikZxTmXXFNOtQYVEhsTQDkbiIEZ0AO0VpSFPkJYkoFhhihhYwzij-ex5gJIgFAc1Jnoot4yYBlkrh1HiEKXiyr7CVkXHTZRz-bNio2MWZ0XMXr8h9MnaJNaEez6IqeoYyAi-gyty696Wn2eu5SA5yR5-Abg2cE7 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Human+Pluripotent+Stem+Cells+in+Neurodegenerative+Diseases%3A+Potentials%2C+Advances+and+Limitations&rft.jtitle=Current+stem+cell+research+%26+therapy&rft.au=Kolagar%2C+Tannaz+Akbari&rft.au=Farzaneh%2C+Maryam&rft.au=Nikkar%2C+Negin&rft.au=Khoshnam%2C+Seyed+Esmaeil&rft.date=2020-01-01&rft.eissn=2212-3946&rft.volume=15&rft.issue=2&rft.spage=102&rft_id=info:doi/10.2174%2F1574888X14666190823142911&rft_id=info%3Apmid%2F31441732&rft_id=info%3Apmid%2F31441732&rft.externalDocID=31441732 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2212-3946&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2212-3946&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2212-3946&client=summon |